Pioglitazone and cardiovascular outcomes in patients with insulin resistance, pre-diabetes and type 2 diabetes: a systematic review and meta-analysis

Conclusions
Pioglitazone was associated with reduced risk of MACE in people with insulin resistance, pre-diabetes and diabetes mellitus. However, the risks of heart failure, bone fracture, oedema and weight gain were increased.

Source: BMJ Open - January 4, 2017 Category: Journals (General) Authors: Liao, H.-W., Saver, J. L., Wu, Y.-L., Chen, T.-H., Lee, M., Ovbiagele, B. Tags: Open access, Cardiovascular medicine, Diabetes and Endocrinology Research Source Type: research